TSC-102

N/A

Report date: 2026/02/27 20:01:47

Base Information

Drug NameTSC-102
Drug Alias NameTSC-102-A0301TSC-102TSC-102-A01TSC-102-A03
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionLeukocyte common antigen modulators
TargetsLeukocyte common antigen
Therapy Area/IndicationsMyelodysplastic SyndromesHematologic NeoplasmsLeukemia, Myeloid, Acute +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesTScan Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTScan Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesHematologic NeoplasmsLeukemia, Myeloid, Acute +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A